SCHEMBL6192244

SCHEMBL6192244

CCOC(=O)N1C=NC=CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 7/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
MAPT P10636 3/20 0.32
ABL1 P00519 1/20 0.32
RIN1 Q13671 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 3/20 0.31
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 1/20 0.31
GAA P10253 2/20 0.31
LPO P22079 2/20 0.31
RECQL P46063 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933258 0.72
SCHEMBL4771331 0.70 TSHR (0.35) TSHRKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL8436272 0.70 ALDH1A1 (0.42) TSHRKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL6252197 0.69 MEN1 (0.36) KMT2AALDH1A1SMN1; SMN2HTTKDM4E
Hydrochloric Acid SCHEMBL4774116 0.69 TSHR (0.34) TSHRKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL31503973 0.66 TSHR (0.50) TSHRKMT2AALDH1A1FAAHMGLL
SCHEMBL28187319 0.64 ALDH1A1 (0.41) TSHRKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL4283831 0.62
Hydrochloric Acid SCHEMBL17730390 0.62
SCHEMBL6192241 0.61 TSHR (0.33) TSHRKMT2AALDH1A1FAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116265467-B Intermediate for synthesizing TYK2 inhibitor, and preparation method and application thereof 成都科岭源医药技术有限公司 2025-04-18 CN disclosed
CN-116829562-B Macrocyclic compound, pharmaceutical composition and application thereof 深圳国顺康医药科技有限公司 2025-04-01 CN disclosed
CN-113527298-B Macrocyclic lactam derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2025-01-03 CN disclosed
US-20240270759-A1 Preparation of SHP2 phosphatase inhibitors and its applications YA THERAPEUTICS INC (CN) 2024-08-15 US disclosed
CN-117886813-A SHP2 phosphatase allosteric inhibitors 药雅科技(上海)有限公司 2024-04-16 CN disclosed
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-117756848-A TH-302 derivative and preparation method thereof 常州大学 2024-03-26 CN disclosed
CN-113727984-B Macrocyclic derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2024-03-15 CN disclosed
CN-112204029-B Therapeutic compounds 豪夫迈·罗氏有限公司 2024-03-01 CN disclosed
CN-115052660-B Substituted 7- (methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide derivatives 伊莱利利公司 2024-01-09 CN disclosed
CN-111253406-A Preparation method of medical intermediate dihydrobenzo [4, 5] imidazo [1, 2-a ] pyrimidine derivative 南京欣久医药科技有限公司 2020-06-09 CN disclosed
CN-111094292-A Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators 豪夫迈·罗氏有限公司 2020-05-01 CN disclosed
WO-2020063965-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR 南京明德新药研发有限公司 2020-04-02 WO disclosed
CN-107207514-B Fused heteroaryl compounds and their use as TRK inhibitors 康联制药有限公司 2020-01-24 CN disclosed
CN-110577549-A Macrocyclic compounds 焦玉奇 2019-12-17 CN disclosed
WO-2019233461-A1 TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏威凯尔医药科技有限公司 (CN) 2019-12-12 WO disclosed
CN-1771231-B Calcium receptor modulating compounds and uses thereof TAKEDA CHEMICAL INDUSTRIES LTD 2011-05-25 CN disclosed
CN-1771231-A Calcium receptor modulating compounds and uses thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-05-10 CN disclosed
EP-1511751-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS Neogenesis Pharmaceuticals, Inc. (US) 2005-03-09 EP disclosed
WO-2003101993-A1 PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS, INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270759-A1 Preparation of SHP2 phosphatase inhibitors and its applications PTPN2, PTPN22, PTPN5 TSHR 988/4885KMT2A 691/4885ALDH1A1 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.